gp130/IL6ST Protein, Mouse (595a.a, HEK293, His)

Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family^[1]. gp130 inhibits the cell growth and migration^[3], decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity^[4][5]. gp130/IL6ST Protein, Mouse (595a.a, HEK293, His) is a recombinant protein with a His label that consists of 595 amino acids (Q23-E617) and is produced by HEK293 cells.

Glycoprotein 130 mRNA is ubiquitously expressed in the human body,exhibiting highest levels in saphenous vein, pericardium, ovary, omental adipose tissue, peritoneum, spleen lymphnodes, and trigeminal ganglia. And gp130 expression is significantly increased in adult organs compared to fetal organs. Moreover, gp130 is highly expressed in multiple types of cancers compared to normal tissues^[3].
The amino acid sequence of human gp130 protein has low homology between mouse and rat gp130 protein.
gp130 signaling is initiated when autocrine or paracrine cyto-kines induce the dimerization of gp130 and an α-receptor subunit to form the receptor complex, leading to185the activation of downstream signaling cascades, such as the JAK/STAT, the PI3K/Akt, and the Ras/Raf/Mek/Erk1/2MAPK pathways. The activation of JAK/Stat3 pathway induces its target gene expression, resulting in cell growth and proliferation (cyclin D, CDC25 A, c-Myc, survivin), survival (survivin, Bcl-2, Bcl-X_L), angiogenesis (VEGF), and cell migration (MMP-2, MMP-7, and MMP-9)^[3]. gp130 is a IL-6 antagonist shows anti-tumor, anti-inflammation and antinociceptive activity^[4]. gp130 decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67^[5].

Mouse

HEK293

C-10*His

NP_034690/Q00560 (Q23-E617)

16195  [NCBI]

QLLEPCGYIYPEFPVVQRGSNFTAICVLKEACLQHYYVNASYIVWKTNHAAVPREQVTVINRTTSSVTFTDVVLPSVQLTCNILSFGQIEQNVYGVTMLSGFPPDKPTNLTCIVNEGKNMLCQWDPGRETYLETNYTLKSEWATEKFPDCQSKHGTSCMVSYMPTYYVNIEVWVEAENALGKVSSESINFDPVDKVKPTPPYNLSVTNSEELSSILKLSWVSSGLGGLLDLKSDIQYRTKDASTWIQVPLEDTMSPRTSFTVQDLKPFTEYVFRIRSIKDSGKGYWSDWSEEASGTTYEDRPSRPPSFWYKTNPSHGQEYRSVRLIWKALPLSEANGKILDYEVILTQSKSVSQTYTVTGTELTVNLTNDRYVASLAARNKVGKSAAAVLTIPSPHVTAAYSVVNLKAFPKDNLLWVEWTPPPKPVSKYILEWCVLSENAPCVEDWQQEDATVNRTHLRGRLLESKCYQITVTPVFATGPGGSESLKAYLKQAAPARGPTVRTKKVGKNEAVLAWDQIPVDDQNGFIRNYSISYRTSVGKEMVVHVDSSHTEYTLSSLSSDTLYMVRMAAYTDEGGKDGPEFTFTTPKFAQGEIE

80-100 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.

• [1]. Cao Y, et al. Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. Sci Rep. 2016 Dec 5;6:38364.  [Content Brief]

  [2]. Nogueira-Silva C, et al. The role of glycoprotein 130 family of cytokines in fetal rat lung development. PLoS One. 2013 Jun 24;8(6):e67607.  [Content Brief]

  [3]. Xu S, et al. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets. 2013 Nov;17(11):1303-28.  [Content Brief]

  [4]. Boettger MK, et al. Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthritis Res Ther. 2010;12(4):R140.  [Content Brief]

  [5]. Hong J, et al. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci Rep. 2016 Apr 15;6:24397.  [Content Brief]